210 related articles for article (PubMed ID: 1377186)
1. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
2. Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells.
Lorico A; Rappa G; Sartorelli AC
Int J Cancer; 1992 Dec; 52(6):903-9. PubMed ID: 1334054
[TBL] [Abstract][Full Text] [Related]
3. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
Woynarowski JM; Sigmund RD; Beerman TA
Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925
[TBL] [Abstract][Full Text] [Related]
7. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16).
Rappa G; Shyam K; Lorico A; Fodstad O; Sartorelli AC
Oncol Res; 2000; 12(3):113-9. PubMed ID: 11216669
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM
Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
11. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
Fernandes DJ; Danks MK; Beck WT
Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
[TBL] [Abstract][Full Text] [Related]
12. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
[TBL] [Abstract][Full Text] [Related]
13. The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
Constantinou A; Grdina D; Kiguchi K; Huberman E
Exp Cell Res; 1992 Nov; 203(1):100-6. PubMed ID: 1330653
[TBL] [Abstract][Full Text] [Related]
14. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
[TBL] [Abstract][Full Text] [Related]
15. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.
Danks MK; Qiu J; Catapano CV; Schmidt CA; Beck WT; Fernandes DJ
Biochem Pharmacol; 1994 Nov; 48(9):1785-95. PubMed ID: 7980648
[TBL] [Abstract][Full Text] [Related]
16. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
Baloch Z; Cohen S; Coffman FD
J Immunol; 1990 Nov; 145(9):2908-13. PubMed ID: 2170526
[TBL] [Abstract][Full Text] [Related]
18. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
20. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
